Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity

Structure

Volumn 11, Issue 7, 2003, Pages 865-873

  Huai, Qing ^a   Wang, Huanchen ^a   Sun, Yingjie ^a   Kim, Hwa Young ^a   Liu, Yudong ^a   Ke, Hengming ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; ROLIPRAM; SILDENAFIL;

ARTICLE; BINDING AFFINITY; CATALYSIS; CONFORMATION; CRYSTAL STRUCTURE; HYDROGEN BOND; MOLECULAR RECOGNITION; MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE;

EID: 0038154006     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(03)00123-0     Document Type: Article

References (44)

1. Antoni F. Molecular diversity of cyclic AMP signaling. Front. Neuroendocrinol. 21:2000;103-132.
2. Atienza J.M., Susanto D., Huang C., McCarty A.S., Colicelli J. Identification of inhibitor specificity determinants in a mammalian phosphodiesterase. J. Biol. Chem. 274:1999;4839-4847.
3. Barnette M.S., Bartus J.O., Burman M., Christensen S.B., Cieslinski L.B., Esser K.M., Prabhakar U.S., Rush J.A., Torphy T.J. Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. Biochem. Pharmacol. 51:1996;949-956.
4. Barnette M.S., Underwood D.C. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Curr. Opin. Pulm. Med. 6:2000;164-169.
5. Bobon D.et al. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double-dummy study between rolipram and desipramine in hospitallized major and/or endogenous depressives. Eur. Arch. Psychiatry Neurol. Sci. 238:1988;2-6.
6. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S.et al. Crystallography and NMR System. a new software suite for macromolecular structure determination Acta Crystallogr. D Biol. Crystallogr. 54:1998;905-921.
7. CCP4 The CCP4 (Collaborative Computational Project 4) suite. programs for protein crystallography Acta Crystallogr. D Biol. Crystallogr. 50:1994;760-763.
8. Conti M., Jin S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63:1999;1-38.
9. Corbin J.D., Francis S.H. Cyclic GMP phosphodiesterase-5. target of sildenafil J. Biol. Chem. 274:1999;13729-13732.
10. Corbin J.D., Francis S.H. Pharmacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Pract. 56:2002;453-459.
11. Demnitz J., LaVecchia L., Bacher E., Keller T.H., Müller T., Schürch F., Weber H.P., Pombo-Villar E. Enantiodivergent synthesis of (R)- and (S)-rolipram. Molecules. 3:1998;107-119.
12. Dym O., Xenarios I., Ke H., Colicelli J. Molecular docking of competitive phosphodiesterase inhibitors. Mol. Pharmacol. 61:2002;20-25.
13. Giembycz M.A. Phosphodiesterase 4 inhibitors and the treatment of asthma. Drugs. 59:2000;193-212.
14. Giembycz M.A. Development status of second generation PDE 4 inhibitors for asthma and COPD. the story so far Monaldi Arch. Chest Dis. 57:2002;48-64.
15. Houslay M.D. Adaptation in cyclic AMP signaling processes. a central role for cyclic AMP phosphodiesterases Semin. Cell Dev. Biol. 9:1998;161-167.
16. Houslay M.D., Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem. Sci. 22:1997;217-224.
17. Houslay M.D., Sullivan M., Bolger G.B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family. intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions Adv. Pharmocol. 44:1998;225-343.
18. Huang Z., Ducharme Y., Macdonald D., Robichaud A. The next generation of PDE4 inhibitors. Curr. Opin. Chem. Biol. 5:2001;432-438.
19. Jones T.A., Zou J.-Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:1991;110-119.
20. Kleinman E.F., Campbell E., Giordano L.A., Cohan V.L., Jenkinson T.H., Cheng J.B., Shirley J.T., Pettipher E.R., Salter E.D., Hibbs T.A.et al. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF inhibitory activity of two series of rolipram analogues. implications for a new active site model of PDE4 J. Med. Chem. 41:1998;266-270.
21. Laliberte F., Han Y., Govindarajan A., Giroux A., Liu S., Bobechko B., Lario P., Bartlett A., Gorseth E., Gresser M.et al. Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry. 39:2000;6449-6458.
22. Lario P.I., Bobechko B., Bateman K., Kelly J., Vrielink A., Huang Z. Purification and characterization of the human PDE4A catalytic domain (PDE4A330-723) expressed in Sf9 cells. Arch. Biochem. Biophys. 394:2001;54-60.
23. Lee M.E., Markowitz J., Lee J.O., Lee H. Crystal structure of phophodiesterase 4D and inhibitor complex. FEBS Lett. 530:2002;53-58.
24. Liu S., Laliberte F., Bobechko B., Bartlett A., Lario P., Gorseth E., Van Hamme J., Gresser M.J., Huang Z. Dissecting the cofactor-dependent and independent binding of PDE4 inhibitors. Biochemistry. 40:2001;10179-10186.
25. Manganiello V.C., Taira M., Degerman F., Belfrage P. Type III cGMP-inhibited cyclic nucleotide phosphodiesterase (PDE3 gene family). Cell. Signal. 7:1995;445-455.
26. Mehats C.M., Anderson C.B., Filopanti M., Jin S.L.C., Conti M. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol. Metab. 13:2002;29-35.
27. Müller T., Engels P., Fozard J.R. Subtypes of type 4 cAMP phosphodiesterase. structure, regulation and selective inhibition Trends Pharmacol. Sci. 17:1996;294-298.
28. Navaza J., Saludjian P. AMoRe. an automated molecular replacement program package Methods Enzymol. 276:1997;581-594.
29. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1997;307-326.
30. Piaz V.D., Giovannoni P. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. Eur. J. Med. Chem. 35:2000;463-480.
31. Reilly M.P., Mohler E.R. III. Cilostazol. treatment of intermittent claudication Ann. Pharmacother. 35:2001;48-56.
32. Richter W., Unciuleac L., Hermsdorf T., Kronbach T., Dettmer D. Identification of inhibitor binding of the cAMP-specific phosphodiesterase 4. Cell. Signal. 13:2001;287-297.
33. Rocque W.J., Tian G., Wiseman J.S., Holmes W.D., Zajac-Thompson I., Willard D.H., Patel I.R., Wisely G.B., Clay W.C., Kadwell S.H.et al. Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. Biochemistry. 36:1997;14250-14261.
34. Rotella D.P. Phosphodiesterase 5 inhibitors. current status and potential applications Nat. Rev. Drug Discov. 1:2002;674-682.
35. Scott A.I., Perini A.F., Shering P.A., Whalley I.L. In-patient major depression. is rolipram as effective as amitriptyline? Eur. J. Clin. Pharmacol. 40:1991;127-129.
36. Soderling S.H., Beavo J.A. Regulation of cAMP and cGMP signaling. new phosphodiesterases and new functions Curr. Opin. Cell Biol. 12:2000;174-179.
37. Souness J.E., Aldous D., Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phophodiesterase (PDE) type 4 inhibitors. Immunopharmacology. 47:2000;127-162.
38. Sturton G., Fitzgerald M. Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest. 121:2002;192s-196s.
39. Thompson W.J. Cyclic nucleotide phosphodiesterases. pharmacology, biochemistry and function Pharmacol. Ther. 51:1991;13-33.
40. Torphy T.J. Phosphodiesterase isozymes. molecular targets for novel antiasthma agents Am. J. Respir. Crit. Care Med. 157:1998;351-370.
41. Torphy T.J., Stadel L.M., Burman M., Cieslinski L.B., Mclaughlin M.M., White J., Livi G.P. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J. Biol. Chem. 267:1992;1798-1804.
42. Underwood D.C., Kotzer C.J., Bochnowicz S., Osborn R.R., Luttmann M.A., Hay D.W., Torphy T.J. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J. Pharmacol. Exp. Ther. 270:1994;250-259.
43. Xu R.X., Hassell A.M., Vanderwall D., Lambert M.H., Holmes W.D., Luther M.A., Rocque W.J., Milburn M.V., Zhao Y., Ke H.et al. Atomic structure of PDE4. insight into phosphodiesteras mechanism and specificity Science. 288:2000;1822-1825.
44. Zhao A.Z., Yan C., Sonnenburg W.K., Beavo J.A. Recent advances in the study of Ca 2+/Cam-activated phosphodiesterases. Signal Transduct. Health Dis. 31:1997;237-251.